Kinase News and Research

RSS

Sirolimus effective in treating children with Pretzel syndrome, new study reports

With a better understanding of underlying mechanisms that cause a rare neurodevelopmental disorder in the Old Order Mennonite population, referred to as Pretzel syndrome, a new study reports that five children were successfully treated with a drug that modifies the disease process, minimizing seizures and improving receptive language.

25 Apr 2013

Researchers find tumors with ALK rearrangements can harbor additional mutations

The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment.

23 Apr 2013

Discovery reverses the prevailing model of how dividing cells monitor equal distribution of chromosomes

Ludwig researchers Arshad Desai and Christopher Campbell, a post-doctoral fellow in his laboratory, were conducting an experiment to parse the molecular details of cell division about three years ago, when they engineered a mutant yeast cell as a control that, in theory, had no chance of surviving. Apparently unaware of this, the mutant thrived.

22 Apr 2013

Aurigene and Endo’s collaborative efforts yield novel drug candidates

Aurigene and Endo entered into collaboration in 2009, for multiple integrated drug discovery programs in the areas of Inflammation and Oncology.

22 Apr 2013

Advanced microscope reveals process where mutations lead to autism and other diseases

Using spinning disk microscopy on barely day-old zebra fish embryos, University of Oregon scientists have gained a new window on how synapse-building components move to worksites in the central nervous system.

22 Apr 2013

Study identifies potential drug targets that interfere with cancer metabolism

A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.

22 Apr 2013

Shc plays key role in activating and controlling Erk

A protein which is intimately involved in cancer-promoting cell signaling also keeps a key component of the signaling pathway tied down and inactive, a team led by scientists from The University of Texas MD Anderson Cancer Center reports this week in Nature Structural Molecular Biology.

20 Apr 2013

Three MGH projects named among Top 10 Clinical Research Achievements of 2012

Three projects led by Massachusetts General Hospital investigators have been named among the Clinical Research Forum's Top 10 Clinical Research Achievements of 2012.

19 Apr 2013

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase.

18 Apr 2013

Research: Transcription factors regulating oxygen levels in blood play a role in melanoma metastases

Researchers at the University of North Carolina have discovered that transcription factors regulating the levels of oxygen in the blood also play a role in the spread of the skin cancer melanoma.

17 Apr 2013

Researchers identify gene mutations responsible for subtype of childhood brain tumor

The St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project has identified mutations responsible for more than half of a subtype of childhood brain tumor that takes a high toll on patients.

15 Apr 2013

Death of heart tissue could be prevented with new medicines, say TUSM scientists

A major factor in the advance of heart disease is the death of heart tissue, a process that a team of scientists at Temple University School of Medicine's Center for Translational Medicine think could be prevented with new medicines.

15 Apr 2013

Antipsychotics seemed to normalize gene expression pattern in people with bipolar disorder: Study

Every day, millions of people with bipolar disorder take medicines that help keep them from swinging into manic or depressed moods.

12 Apr 2013

Researchers show how Src kinase influences inner workings of cells

Researchers at the University of North Carolina at Chapel Hill School of Medicine have "rationally rewired" some of the cell's smallest components to create proteins that can be switched on or off by command.

12 Apr 2013

New research reveals how autophagy keeps neural stem cells to replace damaged brain, nerve cells

Deep inside your brain, a legion of stem cells lies ready to turn into new brain and nerve cells whenever and wherever you need them most. While they wait, they keep themselves in a state of perpetual readiness - poised to become any type of nerve cell you might need as your cells age or get damaged.

11 Apr 2013

Pfizer's breast cancer compound wins FDA's Breakthrough Therapy designation

Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration for the potential treatment of patients with breast cancer.

From Pfizer, Inc. 11 Apr 2013

Research opens new avenue for treatment of melanoma

For the first time, scientists have demonstrated the mechanism of action of gossypin, a naturally-occurring substance found in fruits and vegetables, as a treatment for melanoma, which causes the majority of deaths from skin cancer.

11 Apr 2013

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors.

10 Apr 2013

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.

10 Apr 2013

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

The mammalian target of rapamycin, mTOR is a central integrator of the cell that coordinates growth factor receptor signaling with energy and nutrient status to control a wide array of activities, including the regulation of cellular proliferation and survival.

9 Apr 2013

Kinase News and Research

Sirolimus effective in treating children with Pretzel syndrome, new study reports

Researchers find tumors with ALK rearrangements can harbor additional mutations

Discovery reverses the prevailing model of how dividing cells monitor equal distribution of chromosomes

Aurigene and Endo’s collaborative efforts yield novel drug candidates

Advanced microscope reveals process where mutations lead to autism and other diseases

Study identifies potential drug targets that interfere with cancer metabolism

Shc plays key role in activating and controlling Erk

Three MGH projects named among Top 10 Clinical Research Achievements of 2012

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Research: Transcription factors regulating oxygen levels in blood play a role in melanoma metastases

Researchers identify gene mutations responsible for subtype of childhood brain tumor

Death of heart tissue could be prevented with new medicines, say TUSM scientists

Antipsychotics seemed to normalize gene expression pattern in people with bipolar disorder: Study

Researchers show how Src kinase influences inner workings of cells

New research reveals how autophagy keeps neural stem cells to replace damaged brain, nerve cells

Pfizer's breast cancer compound wins FDA's Breakthrough Therapy designation

Research opens new avenue for treatment of melanoma

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News